Surgalign Holdings EBIT

Surgalign Holdings (SRGA) currently reports a EBIT of $-69M as of March 2023. That compares with $-62M in the prior-year period — down 12.2% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore Surgalign Holdings's EBIT history and peer comparisons.

Surgalign Holdings's EBIT decreased from $-62M to $-69M — a 12.2% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Surgalign Holdings's EBIT of $-69M is lower than the Healthcare sector average of $99B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Surgalign Holdings reported $-69M in EBIT as of March 2023. That compares with $-62M in the prior-year period — down 12.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-69M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for Surgalign Holdings, and consider following SRGA for alerts when major investors trade the stock.